Data was provided and reviewed and it was seen that run 73 shows a positive result for sars-cov-2, with a ct value near the limit of detection (lod).Samples at the lod can waver upon retest.Review of the curves/data did not show any abnormalities.The data indicated the pooled sample contains a viral target concentration at the limit of detection for the assay, so discrepancies at this level can be expected with repeat testing.The issue is sample specific and no product problem was identified.(b)(4).Na.
|
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer from australia alleged a discrepant result for a pooled sample while using the cobas® sars-cov-2 & influenza a/b nucleic acid test on the cobas® liat® system.The alleged pooled sample initially generated a positive result for sars-cov-2.Individual samples were tested and generated negative results for sars-cov-2.The same pooled sample was then retested and generated a negative result for sars-cov-2.Because the customer is pooling samples, which is off-label, the alleged false positive result was not reported.No harm was alleged.An investigation was conducted to evaluate the customer issue.
|